Dengvaxia Efficacy Dependency on Serostatus: A Closer Look at More Recent Data.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Mathematical models for dengue fever epidemiology: A 10-year systematic review.Physics of life reviews · 2022
   Pooled it
2. The effect of mixed vaccination rollout strategy: A modelling study.Infectious Disease Modelling · 2023
   Article
3. Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art.The Journal of general virology · 2023
   Review
4. The role of mild and asymptomatic infections on COVID-19 vaccines performance: A modeling study.Journal of advanced research · 2022
   Article
5. Combination of E- and NS1-Derived DNA Vaccines: The Immune Response and Protection Elicited in Mice against DENV2.Viruses · 2022
   Article
6. Modeling the initial phase of COVID-19 epidemic: The role of age and disease severity in the Basque Country, Spain.PloS one · 2022
   Article
7. Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines.Frontiers in immunology · 2022
   Review
8. Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection.Viruses · 2021
   Article
9. Modeling Dengue Immune Responses Mediated by Antibodies: A Qualitative Study.Biology · 2021
   Article
10. Pathogen Dose in Animal Models of Hemorrhagic Fever Virus Infections and the Potential Impact on Studies of the Immune Response.Pathogens (Basel, Switzerland) · 2021
    Review
11. The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study.Vaccines · 2020
    Article
12. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.mBio · 2020
    Article
13. The Optimal Age of Vaccination Against Dengue with an Age-Dependent Biting Rate with Application to Brazil.Bulletin of mathematical biology · 2020
    Article
14. Reply to Aguiar and Stollenwerk.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article

Corrections and comments

• Commented on by
  Reply to Aguiar and Stollenwerk.2018
• Comment on
  Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as